Medical Device Network

Dexcom G6 adds another compatible AID system after Omnipod 5 launch

Dexcom’s CGM device was used exclusively in the clinical trials used to support regulatory approval of Insulet’s new AID system.

Following Insulet's launch of the Omnipod 5 automated insulin delivery (AID) system in the UK, DexCom announced its G6 continuous monitoring (CGM) device will be compatible with the new device.

Dexcom says its device is the first and only CGM that can connect with the Omnipod 5. The G6 was used exclusively in clinical trials that supported the regulatory approval of Insulet’s entrant to the insulin delivery market.

In a market model by GlobalData, the insulin pump market is expected to reach $14bn by 2030.

The Omnipod 5 is the first tubeless hybrid closed-loop system that helps deliver insulin doses automatically to help simplify diabetes management. The Dexcom G6 sends regular blood sugar parameters to the device, which it can then use to adjust insulin delivery doses.

The compatibility with the Omnipod 5 adds to a strong portfolio of connections for the G6 which is a popular CGM of use for diabetes patients. It provides patients with real-time glucose data without the need for a finger prick and can be customised to issue alarms when blood sugar falls outside of set windows.

Dexcom’s UK and Ireland director Ben Byrne told Medical Device Network: “The Dexcom G6 CGM sets the global standard as the first integrated continuous glucose monitor (CGM) authorised to work with a range of connected closed-loop system partners (Omnipod, Tandem t:slim X2, CamAPS FX and YpsoPump) and digital health apps (Glooko and Nudg, Happy Bob and Sugarmate, and most recently, lifestyle devices from Garmin).

“We are continuously working with key stakeholders in the industry, including Nice and the NHS to ensure our technology meets the needs of people with diabetes and is as accessible as possible.”

The UK’s National Institute of Health and Care Excellence (NICE) will now appraise the new device and issue subsequent guidance for its use in the NHS in England.

Diabetes UK policy manager Nikki Joule said: “As we look forward to the outcome of the NICE appraisal expected later this year, which will make hybrid closed-loop more widely available, it’s important that people have a range of systems to choose from to fit their individual needs and circumstances.”

GlobalData is the parent company of Medical Device Network.